Atopy Modifies the Association Between Inhaled Corticosteroid Use and Lung Function Decline in Patients with Asthma.

Allergic sensitization Asthma Atopy Cohort study Epidemiology IgE Inhaled corticosteroids Lung function decline Precision medicine Response to corticosteroids

Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
03 2020
Historique:
received: 16 05 2019
revised: 15 10 2019
accepted: 15 10 2019
pubmed: 11 11 2019
medline: 15 5 2021
entrez: 10 11 2019
Statut: ppublish

Résumé

Inhaled corticosteroids (ICSs) are the mainstay of asthma treatment, but response to medication is variable. Patients with allergic inflammation generally show a better short-term response to ICSs; however, studies on predictors of long-term response are few. To assess whether allergic sensitization can modify the association between ICS use and lung function decline over 20 years in adult asthma. We used data from the 3 clinical examinations of the European Community Respiratory Health Survey. We measured ICS use (no use, and use for <1.3, 1.3-8, and >8 years) and FEV FEV Our study suggests that biomarkers of atopy can predict a more favorable long-term response to ICSs. Randomized controlled studies are needed to confirm these findings.

Sections du résumé

BACKGROUND
Inhaled corticosteroids (ICSs) are the mainstay of asthma treatment, but response to medication is variable. Patients with allergic inflammation generally show a better short-term response to ICSs; however, studies on predictors of long-term response are few.
OBJECTIVE
To assess whether allergic sensitization can modify the association between ICS use and lung function decline over 20 years in adult asthma.
METHODS
We used data from the 3 clinical examinations of the European Community Respiratory Health Survey. We measured ICS use (no use, and use for <1.3, 1.3-8, and >8 years) and FEV
RESULTS
FEV
CONCLUSIONS
Our study suggests that biomarkers of atopy can predict a more favorable long-term response to ICSs. Randomized controlled studies are needed to confirm these findings.

Identifiants

pubmed: 31704441
pii: S2213-2198(19)30914-6
doi: 10.1016/j.jaip.2019.10.023
pii:
doi:

Substances chimiques

Adrenal Cortex Hormones 0

Types de publication

Clinical Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

980-988.e10

Subventions

Organisme : Wellcome Trust
ID : WT 084703MA
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0901214
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : R01 HL056633
Pays : United States
Organisme : Medical Research Council
ID : 92091
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S019669/1
Pays : United Kingdom

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Alessandro Marcon (A)

Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. Electronic address: alessandro.marcon@univr.it.

Pierpaolo Marchetti (P)

Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Josep M Antó (JM)

Institute for Global Health (ISGlobal), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Lucia Cazzoletti (L)

Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Isa Cerveri (I)

Division of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.

Angelo Corsico (A)

Division of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.

Diogenes Seraphim Ferreira (DS)

School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Alergia e Imunologia, Complexo Hospital de Clinicas, Universidade Federal do Parana, Curitiba, Brazil.

Judith Garcia-Aymerich (J)

Institute for Global Health (ISGlobal), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

David Gislason (D)

Department of Allergy, Respiratory Medicine and Sleep, Landspitali University Hospital, Reykjavik, Iceland.

Joachim Heinrich (J)

Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Ludwig, Maximilians University, Munich, Germany; Comprehensive Pneumology Centre Munich, German Centre for Lung Research, Munich, Germany.

Rain Jõgi (R)

Department of Pneumology, University of Tartu, Tartu, Estonia.

Ane Johannessen (A)

Centre for International Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.

Bénédicte Leynaert (B)

Inserm-U1168, VIMA (Aging and Chronic Diseases. Epidemiological and Public Health Approaches), Villejuif, France; UMR-S 1168, UVSQ, Univ Versailles St-Quentin-en-Yvelines, St-Quentin-en-Yvelines, France.

Andrei Malinovschi (A)

Department of Medical Sciences: Clinical Physiology, Uppsala University, Uppsala, Sweden.

Isabelle Pin (I)

Pediatrics, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; INSERM, Institut for Advanced Biosciences, Grenoble, France; Université Grenoble Alpes, Grenoble, France.

Nicole Probst-Hensch (N)

Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.

Joost Weyler (J)

Epidemiology and Social Medicine, StatUA Statistics Center, University of Antwerp, Antwerp, Belgium.

Christer Janson (C)

Department of Medical Sciences: Respiratory, Allergy and Sleep research, Uppsala University, Uppsala, Sweden.

Deborah Jarvis (D)

National Heart and Lung Institute, Imperial College London, London, United Kingdom; MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom.

Simone Accordini (S)

Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH